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Abstract: BACKGROUND A significant proportion of patients with coronavirus disease 19 (COVID-19)
suffer from excessive coagulation activation and coagulopathy which is associated with an increased risk of
venous and arterial thromboembolism and adverse outcome. Our study investigates coagulation markers
and the incidence of thromboembolic events in COVID-19 patients receiving recommended anticoagula-
tion strategies. METHODS In a retrospective single-center analysis at the University Hospital Zurich,
Switzerland, we investigated 31 adult COVID-19 patients between April 6th and May 13th, 2020 and
with at least one laboratory assessment of the coagulation markers prothrombin time/Quick, thrombin
time, fibrinogen and D-dimers. For antithrombotic prophylaxis low-molecular-weight-heparin or unfrac-
tionated heparin was administered and two patients with heparin-induced thrombocytopenia received
argatroban. RESULTS We analyzed 31 patients (68% male, mean age 60± SD 15 years). 22 (71%) of
these required intensive care unit treatment, 5 (16%) were hospitalized in a ward, and 4 (13%) were
outpatients. Mean fibrinogen levels were markedly elevated to 6.4± SD 1.8g/l, with a peak in the third
week of the disease and no significant decrease over time. D-dimers were elevated to a mean value of
5.1±4.4mg/l with peak levels of 6.8±5.3mg/l in the fourth week of disease, and a subsequent decrease.
Platelet count (308±136G/l) and PT/Quick (85±22%) showed no significant changes over time. Sensi-
tivity analyses for patients treated in the ICU showed that D-dimer levels were higher in this group. The
results of other sensitivity analyses were comparable. Thromboembolic events were diagnosed in 4 (13%)
patients and 5 (16%) patients died during the observation period. CONCLUSION We find coagulation
alterations in COVID-19 patients indicating significant hypercoagulability. These alterations are visible
despite antithrombotic treatment, and peak around week 3-4 of the disease.
DOI: https://doi.org/10.1371/journal.pone.0243409
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A significant proportion of patients with coronavirus disease 19 (COVID-19) suffer from
excessive coagulation activation and coagulopathy which is associated with an increased
risk of venous and arterial thromboembolism and adverse outcome. Our study investigates
coagulation markers and the incidence of thromboembolic events in COVID-19 patients
receiving recommended anticoagulation strategies.
Methods
In a retrospective single-center analysis at the University Hospital Zurich, Switzerland, we
investigated 31 adult COVID-19 patients between April 6th and May 13th, 2020 and with at
least one laboratory assessment of the coagulation markers prothrombin time/Quick, throm-
bin time, fibrinogen and D-dimers. For antithrombotic prophylaxis low-molecular-weight-
heparin or unfractionated heparin was administered and two patients with heparin-induced
thrombocytopenia received argatroban.
Results
We analyzed 31 patients (68%male, mean age 60± SD 15 years). 22 (71%) of these
required intensive care unit treatment, 5 (16%) were hospitalized in a ward, and 4 (13%)
were outpatients. Mean fibrinogen levels were markedly elevated to 6.4± SD 1.8g/l, with a
peak in the third week of the disease and no significant decrease over time. D-dimers
were elevated to a mean value of 5.1±4.4mg/l with peak levels of 6.8±5.3mg/l in the fourth
week of disease, and a subsequent decrease. Platelet count (308±136G/l) and PT/Quick
(85±22%) showed no significant changes over time. Sensitivity analyses for patients treated
in the ICU showed that D-dimer levels were higher in this group. The results of other sensi-
tivity analyses were comparable. Thromboembolic events were diagnosed in 4 (13%)
patients and 5 (16%) patients died during the observation period.
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Conclusion
We find coagulation alterations in COVID-19 patients indicating significant hypercoagulabil-
ity. These alterations are visible despite antithrombotic treatment, and peak around week
3–4 of the disease.
Background
Coronavirus disease 19 (COVID-19) is caused by infection with Severe Acute Respiratory Syn-
drome Corona Virus-2 (SARS-CoV-2). It was first discovered in December 2019 in Wuhan,
China, and has since spread worldwide resulting so far in over 41 million infected persons and
over 1 million deaths [1, 2]. Symptoms as fever, cough, shortness of breath, fatigue and pneu-
monia are described [1, 3]. SARS-CoV-2 is transmitted principally by aerosol. An increasing
number of studies indicate that COVID-19 is, however, not only a respiratory disease. SARS-
CoV-2 may directly infect endothelial cells thereby causing endotheliitis [4], and COVID-19 is
associated with a marked coagulation activation and an increased risk of venous and arterial
thromboembolism [5, 6]. To this regard an initial elevation of D-dimers, a marker of coagula-
tion activation and fibrinolysis, is indicative of a poor prognosis [7]. A potential prognostic
value of other coagulation parameters is poorly understood. Recognizing their increased risk
of thromboembolism, the Swiss Society of Hematology’s (SSH) Working Party Hemostasis has
among other national and international societies issued a guideline recommending thrombo-
prophylaxis in all hospitalized COVID-19 patients [8, 9], preferentially with low molecular
weight-heparin (LMWH) and with a dose increase if additional prothrombotic risk factors are
present. This guideline also suggests daily coagulation monitoring including prothrombin
time (PT) / Quick, D-dimers, fibrinogen, and platelet count. It was put into effect in our Uni-
versity Hospital on April 7th and updated on May 25th, 2020. Our study investigates laboratory
markers of coagulopathy in COVID-19 patients receiving antithrombotic treatment, and the
incidence of thromboembolic events.
Methods
This study was approved and the requirement for written informed consent was waived by the
local ethics committee (Kantonale Ethikkommission Zurich, BASEC no. 2020–00849). Data
were handled according to the Good Clinical Practice Guidelines. We encrypted our database
after data collection was completed. Statistical analysis was performed with encrypted data
only.
Study design
The study is a retrospective single-center study carried out at the University Hospital Zurich,
Switzerland. It includes adult patients with confirmed SARS-CoV-2 infection, diagnosed
between April 6th and May 13th, 2020, and with at least one standardized assessment of coagu-
lation markers.
Standardized coagulation monitoring was recommended on a daily base and by a prede-
fined set of parameters; its execution was, however, left to the attending physicians’ discretion.
Patients were not included if they refused to participate, or if standardized coagulation analysis
was not available. The study was approved by the local ethics committee.
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Study endpoints
Our primary goal was the investigation of COVID-19 associated coagulopathy during the
course of disease, as visualized by a standardized set of coagulation parameters (PT/Quick,
thrombin time, fibrinogen, D-dimers and platelet count). In addition, we assessed the inci-
dence of in-hospital thromboembolic events.
COVID-19 coagulation analyses and anticoagulation strategy
A set of coagulation parameters was predefined according to the SSH recommendations which
included PT/Quick, thrombin time, fibrinogen, and D-dimers [8]. Coagulation analyses were
performed in platelet-poor citrated plasma using a CS-5100 coagulation analyser (Siemens,
Marburg, Germany). Prothrombin time as tissue-factor induced coagulation time was per-
formed using Innovin (Siemens, Marburg, Germany) as a thromboplastin reagent. As it is con-
vention in German-speaking countries, the prothrombin time is displayed as Quick value (%
of a normal plasma pool) and as international normalized ratio (INR). Thrombin time was
determined using Thromboclotin as thrombin reagent (Siemens, Marburg, Germany). Fibrin-
ogen concentration was determined by functional assay according to Clauss (Multifibren U,
Siemens, Marburg, Germany). D-dimers were determined by immuno-turbidimetric assay
(Innovance D-Dimers, Siemens, Marburg, Germany).
Daily standardized coagulation monitoring was suggested, but execution was left to the
attending physicians’ discretion. All hospitalized COVID-19 patients received LMWH or UFH
at a prophylactic to intermediate (thromboprophylaxis) or therapeutic (acute thromboembo-
lism, extracorporeal membrane oxygenation [ECMO]) level. Two patients with suspected hep-
arin-induced thrombocytopenia received argatroban. Anti Xa activity (for heparins) and anti
IIa activity (for argatroban) was monitored when indicated. Use of direct oral anticoagulants
was not documented in this context.
Variables and data collection
Medical records of all COVID-19 positive patients receiving at least one laboratory COVID-19
coagulation assessment were reviewed. The following parameters were extracted from the hos-
pital’s clinical information system: age, sex, date of initial diagnosis of COVID-19, date and
time of blood withdrawal, D-dimers, fibrinogen, PT / Quick, platelet count, thrombin time,
anti-factor Xa activity, c-reactive protein (CRP), patient category (ICU, ward, outpatient),
duration of hospitalization, outcome (death, discharge, ongoing hospitalization), type of anti-
coagulant (LMWH, UFH, argatroban), pre-existing comorbidities grouped by organ system
(cardiovascular, pulmonal, diabetes, renal, obesity, coagulation disorders, neoplasia), and com-
plications during hospital stay (pulmonary embolism, deep vein thrombosis, acute kidney
injury, encephalopathy, cardiovascular complications, and hepatopathy).
Statistical analysis
Categorical data are reported as frequency and percent and numerical data as mean with stan-
dard deviation. To avoid a potential bias of patients with multiple repetitive measurements,
the mean value per week and patient was calculated and entered into the figures. Boxplots
were used to descriptively show the development of the different coagulation parameters over
time. Note that the mean value of each patient per week was entered in these plots so that each
patient contributed only one value per week.
To assess the course of the coagulation parameters over time including all longitudinal mea-
surements of the same patients and thus taking into account that these values are not
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Abbreviations: ARDS, acute respiratory distress
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heparin.
independent, linear mixed models with random intercept per patient were calculated includ-
ing the day since disease onset as covariate. As the course of the D-dimers suggested a rather
quadratic than linear development over time, the day since disease onset was additionally
included as quadratic term. In the model for the course of fibrinogen, the natural logarithm of
CRP was included in addition to the time variable. An additional model for thrombin time
was calculated including UFH, argatroban and type of stay. To take the upper detection limit
for fibrinogen, quick and d-dimer into account, a mixed tobit model was applied to analyze
these parameters. All statistical analyses were performed with R (Version 3.6.2, R Foundation
for Statistical Computing). A p-value of<0.05 was considered statistically significant.
Results
According to inclusion and exclusion criteria, 31 patients were analyzed. Mean age was
60 ± 15 years, and 68% were male. The most frequent pre-existing comorbidities were cardio-
vascular, diabetes, and obesity (Table 1). 22 patients (71%) were treated in the ICU and 5
(16%) in the ward, while 4 (13%) were outpatients. In 5 ICU patients (16%) the development
of a severe acute respiratory distress syndrome (ARDS) required ECMO treatment. 5 patients
(16%) died during the time of observation. The duration of hospitalization is known for 29
patients (48 ± 26 days) while 2 were still hospitalized (Table 1).
All hospitalized patients received pharmacological antithrombotic prophylaxis or therapy
in contrast to none of the outpatients. As antithrombotic drug, UFH was administered in all
but 2 patients (6%) who received LMWH. 2 (6%) patients were switched from UFH to argatro-
ban when a heparin-induced thrombocytopenia was suspected (Table 1).
Table 1. Patient overview (n = 31).
Age (years) 60 ± 15
Sex male 21 68%





coagulation disorder 1 3%
neoplasia 5 16%
Type of stay outpatient 4 13%
ward 5 16%
ICU 22 71%
ICU patient with ECMO 5 16%
Unfractioned heparin therapeutic 14 45%
prophylactic 9 6%
Low molecular heparin prophylactic 2 6%
Argatroban therapeutic 2 6%
No anticoagulation 4 13%
Duration of hospitalisation (days, n = 29) 48 ± 26
In-hospital mortality 5 16%
Duration of hospitalization is reported for 29 patients, while 2 patients are still hospitalized. 4 outpatients did not
receive anticoagulants. Data is presented as count and percentage or mean with standard deviations.
https://doi.org/10.1371/journal.pone.0243409.t001
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Coagulation monitoring showed a hypercoagulable state, despite antithrombotic prophy-
laxis or therapy in all hospitalized patients. For detailed visualizations of PT/Quick, thrombin
time, fibrinogen, D-dimers, and platelet count during the course of disease see Fig 1.
Fibrinogen was markedly elevated to a mean level of 6.4 ± 1.8 g/l, with the highest values in
the third week of disease. Also, CRP was elevated to a mean level of 131 ± 106 mg/l. The tobit
regression model showed a significant change of fibrinogen over the observation time (-0.02,
95% CI -0.04 to -0.01; p = 0.0051) if no other variables were included and also if adjusted for
log(CRP) (0.03, 95% CI 0.01 to 0.05; p = 0.0003). The model additionally shows very strong
evidence for an impact of log(CRP) on the fibrinogen levels (1.37, 95% CI 1.17 to 1.57;
p<0.0001). Sensitivity analyses for the group of ICU patients showed comparable results (S1
Material). Fig 2 shows a scatterplot of the CRP and fibrinogen values for all patients (left) and
for the ICU patients only (right). The red line is the predicted regression line from the mixed
tobit regression model and illustrates the relation between the two values.
D-dimers were elevated to a mean value of 5.1 ± 4.4 mg/l with a continuous increase over
time, peak levels of mean 6.8 ± 5.3 mg/l in the fourth week of disease, and a subsequent
decrease. The tobit regression model shows significant changes of D-dimer levels over time
(linear coefficient 0.35, 95% CI 0.24 to 0.47; p<0.0001). Fig 3 shows the predicted course over
time derived from the tobit regression model for all patients (left) and for ICU patients only
(right).
Platelet count and PT/Quick did not show a significant change over time (0.68, 95%
CI -1.07 to 2.42, p = 0.44 and 0, 95% CI -0.09 to 0.09; p = 0.96, respectively) (Fig 1).
Fig 1 shows an almost linear increase of the thrombin time over time, confirmed by a
regression model indicating a significant increase of 0.66 seconds per disease day (95% CI 0.17
to 1.15, p = 0.008). However, this increase was reduced when anticoagulants were considered
as additional explanatory variables in the regression model (S1 Table in S1 Material). The
increase of the thrombin time may therefore to the most extent be attributed to an effect of
anticoagulation.
During the observation period we diagnosed 5 (16%) new thromboembolic events in 4
(13%) patients. Other complications during that time included acute kidney injury, hepatopa-
thy, cardiac arrythmias, encephalopathy, COVID-19 associated acute myocardial injury and
cardiac arrest (Table 2).
Discussion
Our retrospective single-center study investigated coagulation markers in COVID-19 patients
during the course of disease, and the diagnosis of thromboembolic events during their hospi-
talization. Our findings confirm a marked procoagulatory state which is observed despite rou-
tine antithrombotic treatment and shows a peak around week 3 to 4 of the disease. Sensitivity
analyses for ICU patients only showed that these patients may have higher D-dimer levels.
COVID-19 associated alterations of hemostasis is multifactorial including systemic inflam-
mation and activation of the complement system [10, 11]. According to Iba et al. [12], throm-
bus formation in COVID-19 patients is caused by four major factors: first, COVID-19 induces
a cytokine storm which activates coagulation. Second, the fibrinolytic system is suppressed.
Third, platelets are activated by the cytokine storm and fourth, endothelial damage induced by
inflammation binds platelets and further accelerates the thrombotic reaction. These mecha-
nisms culminate in a hypercoagulability which is a key issue of COVID-19 patients [6, 13–16].
Elevation and rapid increase of D-dimers indicates a procoagulatory state and was also shown
to be an independent predictor for thromboembolic events [10, 16, 17]. Elevated D-Dimer lev-
els are not only a marker of coagulation activation and fibrinolysis, they were also shown to be
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Fig 1. Weekly boxplots of D-dimer, PT/Quick, fibrinogen, thrombin time, anti-Xa activity and platelet count during the
course of disease of 31 COVID-19 patients. To avoid a potential bias of patients with multiple repetitive measurements,
only the mean value per week and patient was entered in the figures.
https://doi.org/10.1371/journal.pone.0243409.g001
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an independent prognostic predictor regarding the in-hospital mortality [1, 18]. D-dimers
may therefore be a helpful marker to guide the clinical management of COVID-19 patients [1,
18]. In line with these findings, we find elevated D-dimers already upon hospital admission
and observe their further increase with a peak around week 4. Our sensitivity analyses of ICU
patients showed that despite antithrombotic treatment these patients may even have higher D-
dimers. According to recent guideline recommendations, this could be an argument for an
early increase of the heparin dose from a prophylactic to an intermediate level in patients who
Fig 2. Relation of CRP and fibrinogen levels of 31 COVID-19 patients. The scatterplot on the left (a) shows the analysis of all patients and the graph
on the right (b) shows the sensitivity analysis for ICU patients only with comparable results. The red line shows the predicted values from a mixed tobit
model including day of illness (here day 27) and log(CRP).
https://doi.org/10.1371/journal.pone.0243409.g002
Fig 3. Predicted D-dimer course during the course of disease of 31 COVID-19 patients. The scatterplot on the left (a) shows the analysis of all
patients and the graph on the right (b) shows the sensitivity analysis for ICU patients only. The red line shows the predicted D-dimer course obtained
from a mixed tobit model, where day of illness is entered both with a linear and a quadratic term. The sensitivity analysis of ICU patients only (b) shows
that patients with a severe course of disease may have higher D-dimer levels.
https://doi.org/10.1371/journal.pone.0243409.g003
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are critically ill or show additional prothrombotic risk factors [16]. However, D-dimer levels
alone are not recommended to guide an individual anticoagulation therapy [10].
Fibrinogen is acting as a mediator of platelet aggregation, red cell adhesion, and thrombosis
[19]. It is also an acute phase reactant produced in the liver and fibrinogen levels can therefore
be a useful monitoring tool of the inflammatory state [20]. As mentioned above, the infection
with coronavirus induces a cytokine storm [11] and interleukin-6 is a major initiator of the
acute phase response [21, 22]. Ranucci et al. described a significant association of interleukin-6
with fibrinogen levels [23]. At the beginning of an acute phase reaction fibrinogen’s function
seems to be predominant to its role in clot formation [24]. The in the course induced hyperfi-
brinogenemia has a protective role as part of the host defense against pathogens [24]. However,
a prothrombotic risk factor of a high fibrinogen level is still discussed [19, 25, 26]. Accordingly,
when correlating CRP and fibrinogen in our study we find an inflammation-induced increased
fibrinogen synthesis. Fibrinogen levels peaked in week three of the disease followed by a slow
decline but were still markable elevated in week eight. In our opinion the persistent inflamma-
tory state of COVID-19 patients contributes to this prolonged hyperfibrinogenemia. A sensi-
tivity analysis of ICU patients showed no noticeable change in the fibrinogen course.
Platelets also play an important role in the clearance of viral pathogens. A unique feature of
COVID-19 is the presence of extramedullary megakaryocytes that actively produce platelets
explaining the continuous high platelet count in our study [27]. Moreover, proinflammatory
cytokines like interleukin-1β or interleukin-6 also increase platelet production and release
[12]. In contrast to our finding it was shown, that COVID-19 patients often suffer from a mild
thrombocytopenia due to an increased platelet consumption together with a corresponding
increase in platelet production [28]. The lack of thrombocytopenia in our study reflects, that
the COVID-19 induced alterations of the hemostasis were not a consumptive coagulopathy—
typical of disseminated intravascular coagulation.
Heparin is known to have also anti-inflammatory properties due to binding inflammatory
cytokines [29]. Moreover, heparin may prevent viral attachment by binding to host or viral
glycoproteins [30]. Several studies have compared the rate of thrombosis in COVID-19
patients with different anticoagulation regimes. Maatman et al. found thromboembolic events
in 28% of patients with severe COVID-19 and concluded that a routine thromboembolism
prophylaxis may therefore be inadequate [31]. Klok et al. found thrombotic complications in
31% of ICU patients and therefore strongly recommended pharmacological thrombosis pro-
phylaxis in all COVID-19 patients [13]. The high incidence of thromboembolic events suggests
an important role of COVID-19-induced coagulopathy [15]. Further studies are needed to
investigate its molecular mechanism and the effect of therapeutic interventions [32]. While Al
Table 2. In-hospital complications of COVID-19 patients (n = 31).
Thromboembolic events (all) 5 16%
Pulmonary embolism 1 3%
Deep vein thrombosis 4 13%
Acute kidney injury 20 65%
Encephalopathy 6 19%
Hepatopathy 8 26%
COVID-19 associated acute myocardial injury 4 13%
Cardiac arrhythmia 7 23%
Cardiac arrest requiring CPR 2 6%
Data is presented as count and percentage.
https://doi.org/10.1371/journal.pone.0243409.t002
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Samkari et al. described a thrombotic complications in 4.8% of COVID-19 patients with stan-
dard doses of prophylactic anticoagulation [14], Helms et al. found 16.7% of thrombotic events
in their study collective and therefore recommended higher anticoagulation targets, especially
in critically ill patients [16]. Compared with these, the incidence of thromboembolism in our
patients was lower. This may in part be due to early antithrombotic treatment by guidelines [8,
9]. However, aiming at further reducing this important complication an increase of prophylac-
tic dose heparin to an intermediate level in selected critically ill patients as suggested by revised
guidelines may prove beneficial. We observed a linear increase of the thrombin time over time
in our patient collective. Our model showed that this increase of the thrombin time may to the
most extent be attributed to an effect of anticoagulation.
Besides the anticoagulation strategy, other factors may influence the occurrence of throm-
boembolic events, such as ethnicity: Liao et al. showed that Europeans have a significantly
higher incidence of VTE compared with Maori, Pacific Island and Asian populations [33].
Moreover, this observation has been described in individuals of different ethnicities living
within the same geographical location. In our opinion it is therefore important to conduct
analyses in different locations to identify other possible confounders.
Limitations
Our study has several limitations. It is a retrospective and single-center study comprising only
a small number of 31 patients. In Switzerland, the first peak of new COVID-19 patients was
reached in April 2020, and numbers decreased substantially at the beginning of May 2020.
Extending our analysis over a longer period would therefore not have added many new cases.
Although we predefined a set of coagulation analyses in order to facilitate a standardized coag-
ulation monitoring this was not universally adopted and not always executed as repetitive
determinations during the course of the disease. To avoid a potential bias of patients with mul-
tiple repetitive measurements, we only entered the mean value per week and patient into the
figures. At the beginning of the COVID pandemia little was known about the associated coa-
gulopathy. At that time, the standardized coagulation monitoring in our hospital included rou-
tine parameters (D-Dimers, PT/Quick, TT, fibrinogen and PLT count). Other parameters of
interest (such as proinflammatory cytokines, markers of the fibrinolysis, or markers of the
anticoagulation system) were determined infrequently and on a case-by-case basis, which lim-
its their availability for analysis. Further studies are necessary to investigate these markers in
more detail. Finally, our patients were not a homogenous collective. Most were severely ill
patients treated in the ICU, but others in the ward or as outpatients. Comparison was limited
by the small number of outpatients (n = 4) and ward patients (n = 5). Therefore, we performed
a sensitivity analysis for ICU patients only.
Conclusion
We observe coagulation alterations in COVID-19 patients indicating a significant hypercoagu-
lability. These are present despite antithrombotic treatment, and peak around week 3–4 of the
disease. ICU patients may even have higher D-dimer levels. This could be an argument for a
prolongation of thromboprophylaxis and for an increased dose in critically ill patients or
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